Efficacy of 15 mg and 50 mg of S18986 on Cognitive Symptoms in Mild Cognitive Impairment Patients Treated Over a 12-month Oral Administration Period.

Trial Profile

Efficacy of 15 mg and 50 mg of S18986 on Cognitive Symptoms in Mild Cognitive Impairment Patients Treated Over a 12-month Oral Administration Period.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs S 18986 (Primary)
  • Indications Mild cognitive impairment
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Apr 2017 Status changed from suspended to discontinued.
    • 15 Nov 2010 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 15 Nov 2010 Planned end date changed to 1 May 2006 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top